[1] Jakab S S, Garcia-Tsao G. Evaluation and management of esophageal and gastric varices in patients with cirrhosis[J]. Clin Liver Dis, 2020, 24(3): 335-350.
[2] Sharara A I, Rockey D C. Gastroesophageal variceal hemorrhage[J]. N Engl J Med, 2001, 345(9): 669-681.
[3] Jakab S S, Garcia-Tsao G. Screening and surveillance of varices in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2019, 17(1): 26-29.
[4] Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis[J]. N Engl J Med, 2010, 362(9): 823-832.
[5] Bosch J, Abraldes J G, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease[J]. Nat Rev Gastroenterol Hepatol, 2009, 6(10): 573-582.
[6] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974.
[7] Garcia-Tsao G, Abraldes J G, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2017, 65(1): 310-335.
[8] La Mura V, Garcia-Guix M, Berzigotti A, et al. A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding[J]. Hepatology, 2020, 72(4): 1353-1365.
[9] Berzigotti A, Rossi V, Tiani C, et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension[J]. J Gastroenterol, 2011, 46(5): 687-695.
[10] A J, A B, G K, et al. Clinical decompensation and outcomes in patients with compensated cirrhosis and a hepatic venous pressure gradient ≥20 mmHg[J]. Am J Gastroenterol, 2020, 115(10):1624-1633.
[11] Moestrup S K, Møller H J. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response[J]. Ann Med, 2004, 36(5): 347-354.
[12] Fouad R, Hamza I, Khairy M, et al. Role of serum soluble CD163 in the diagnosis, risk of bleeding, and prognosis of gastro-esophageal varices in cirrhotic patients[J]. J Interferon Cytokine Res, 2017, 37(3):112-118.
[13] Grønbaek H, Sandahl T D, Mortensen C, et al. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis[J]. Aliment Pharmacol Ther, 2012, 36(2): 173-180.
[14] Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis[J]. Hepatology, 2012, 56(4): 1439-1447.
[15] Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease[J]. Liver Int, 2017, 37(6): 778-793.
[16] Hametner S, Ferlitsch A, Ferlitsch M, et al. The VITRO score (von Willebrand factor antigen/thrombocyte ratio) as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test[J]. PLoS One, 2016, 11(2): e0149230.
[17] Buck M, Garcia-Tsao G, Groszmann R J, et al. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients[J]. Hepatology, 2014, 59(3): 1052-1059.
[18] Wang L, Feng Y, Ma X, et al. Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis[J]. PloS One, 2017, 12(8): e0182969.
[19] Melgar-Lesmes P, Pauta M, Reichenbach V, et al. Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes[J]. Gut, 2011, 60(10): 1404-1411.
[20] Vizzutti F, Romanelli R G, Arena U, et al. ADMA correlates with portal pressure in patients with compensated cirrhosis[J]. Eur J Clin Invest, 2007, 37(6): 509-515.
[21] Sandahl T D, Støy S H, Laursen T L, et al. The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients[J]. PloS One, 2017, 12(12): e0189345.
[22] Kim M Y, Baik S K, Park D H, et al. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study[J]. Liver Int, 2007, 27(8): 1103-1110.
[23] Han S K. Application of ultrasound for the diagnosis of cirrhosis/portal hypertension[J]. J Med Ultrason, 2022, 49(3):321-331.
[24] Benacerraf B R. Three-dimensional volume imaging in gynecology[J]. Obstet Gynecol Clin North Am, 2019, 46(4): 755-781.
[25] Shi K Q, Fan Y C, Pan Z Z, et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease[J]. Liver Int, 2013, 33(1): 62-71.
[26] Selvaraj E A, Mózes F E, Jayaswal A N A, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis[J]. J Hepatol, 2021, 75(4): 770-785.
[27] Cui X W, Li K N, Yi A J, et al. Ultrasound elastography[J]. Endosc Ultrasound, 2022, 11(4): 252-274.
[28] da Silva R G, de Miranda M L Q, de Araújo Caldeira Brant P E, et al. Acoustic radiation force impulse elastography and liver fibrosis risk scores in severe obesity[J]. Arch Endocrinol Metab, 2021, 65(6): 730-738.
[29] Huang Y, Zhao L, He R, et al. A strategy for varices screening based on acoustic radiation force impulse combined with platelet (CHESS2001): an alternative of Baveno Ⅵ criteria[J]. Hepatol Commun, 2022, 6(11): 3154-3162.
[30] Dong B, Chen Y, Lyu G, et al. Quantitative assessment of portal hypertension by two-dimensional shear wave elastography in rat models of nonalcoholic fatty liver disease: comparison with four composite scores[J]. Front Med, 2022, 9: 844558.
[31] Stefanescu H, Rusu C, Lupsor-Platon M, et al. Liver stiffness assessed by ultrasound shear wave elastography from general electric accurately predicts clinically significant portal hypertension in patients with advanced chronic liver disease[J]. Ultraschall Med, 1980, 2020, 41(5): 526-533.
[32] Jansen C, Bogs C, Verlinden W, et al. Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: a prospective multicentre study[J]. Liver Int, 2017, 37(3): 396-405.
[33] Jansen C, Bogs C, Verlinden W, et al. Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study[J]. Gut, 2016, 65(6): 1057-1058.
[34] Park C C, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152(3): 598-607.
[35] Shi Y, Qi Y-F, Lan G-Y, et al. Three-dimensional MR elastography depicts liver inflammation, fibrosis, and portal hypertension in chronic hepatitis B or C[J]. Radiology, 2021, 301(1): 154-162.
[36] Pons M, Augustin S, Scheiner B, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease[J]. Am J Gastroenterol, 2021, 116(4): 723-732.
[37] Perri R E, Chiorean M V, Fidler J L, et al. A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices[J]. Hepatology, 2008, 47(5): 1587-1594.
[38] Wan S, Wei Y, Zhang X, et al. Computed tomography-based texture features for the risk stratification of portal hypertension and prediction of survival in patients with cirrhosis: a preliminary study[J]. Front Med, 2022, 9: 863596.
[39] Wan S, Wei Y, Zhang X, et al. CT-derived quantitative liver volumetric parameters for prediction of severe esophageal varices and the risk of first variceal hemorrhage[J]. Eur J Radiol, 2021, 144: 109984.
[40] Smith A D, Branch C R, Zand K, et al. Liver surface nodularity quantification from routine CT images as a biomarker for detection and evaluation of cirrhosis[J]. Radiology, 2016, 280(3): 771-781.
[41] Bastati N, Beer L, Ba-Ssalamah A, et al. Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD[J]. J Hepatol, 2022, 77(4): 1005-1013.
[42] Zhang D, Deng J, Guo X, et al. Nomogram model for predicting esophsagogastric varices in hepatocellular carcinoma with cirrhosis[J]. Eur J Gastroenterol Hepatol, 2023, 35(3): 342-348.
[43] Kim B H, Chung J W, Lee C S, et al. Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis[J]. Korean J Intern Med, 2019, 34(6): 1233-1243.
[44] Deng H, Qi X, Guo X. Computed tomography for the diagnosis of varices in liver cirrhosis: a systematic review and meta-analysis of observational studies[J]. Postgrad Med, 2017, 129(3): 318-328.
[45] Wang C, Huang Y, Liu C, et al. Diagnosis of clinically significant portal hypertension using CT- and MRI-based vascular model[J]. Radiology, 2023, 307(2): e221648.
[46] Alzoubi O, Arar A, Singh V, et al. MRI in liver cirrhosis[J]. Portal Hypertens Cirrhosis, 2022, 1(1): 23-41.
[47] Palaniyappan N, Cox E, Bradley C, et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging[J]. J Hepatol, 2016, 65(6): 1131-1139.
[48] Pavlides M, Banerjee R, Sellwood J, et al. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease[J]. J Hepatol, 2016, 64(2): 308-315. |
